Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epinastine ophthalmic - AbbVie

Drug Profile

Epinastine ophthalmic - AbbVie

Alternative Names: Alesion LX Ophthalmic Solution; Alesion Ophthalmic Solution; AlesionCream; DE-114; DE-114A; Elestat; Epinastine eye drops; Epinastine hydrochloride; Epinastine hydrochloride high dose; Purivist; Relestat; STN-1011402; STN-1011403

Latest Information Update: 24 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim
  • Developer AbbVie; Santen Pharmaceutical
  • Class Antiallergics; Dibenzazepines; Eye disorder therapies; Imidazoles; Nonsedating antihistamines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Histamine H2 receptor antagonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic conjunctivitis

Most Recent Events

  • 22 May 2024 Launched for Allergic conjunctivitis in Japan (Ophthalmic)
  • 31 Mar 2024 Phase-III clinical trials in Allergic conjunctivitis in China (Ophthalmic) (High dose formulation to instill twice a day)
  • 26 Mar 2024 Registered for Allergic conjunctivitis in Japan (Ophthalmic)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top